Tags

Type your tag names separated by a space and hit enter

Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.

Abstract

High levels of both endocannabinoids and endocannabinoid receptors are present in the basal ganglia. Attention has recently focused on the role of endocannabinoids in the control of movement and in movement disorders of basal ganglia origin such as Parkinson's disease. We investigated CB1 cannabinoid receptor mRNA expression in the reserpine-treated rat model of Parkinson's disease using in situ hybridization. Reserpine treatment caused a topographically organized reduction in CB1 receptor mRNA expression in the striatum (ranging from 11.6% medially to 53.6% laterally and dorsally). No change in CB1 receptor mRNA expression was observed in the cerebral cortex or septum. This reduction in CB1 receptor mRNA expression may be secondary to increased endocannabinoid stimulation of the receptor as increased basal ganglia endocannabinoid levels have been shown to occur in this model of Parkinson's disease. The data support the idea that cannabinoid receptor antagonists may provide a useful treatment for the symptoms of Parkinson's disease.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Division of Neuroscience, University of Manchester, Manchester M13 9PT, United Kingdom.

    , , ,

    Source

    Experimental neurology 169:2 2001 Jun pg 400-6

    MeSH

    Animals
    Autoradiography
    Cannabinoid Receptor Modulators
    Cannabinoids
    Cerebral Cortex
    Corpus Striatum
    Disease Models, Animal
    Gene Expression Regulation
    Humans
    In Situ Hybridization
    Male
    Motor Activity
    Parkinson Disease
    RNA, Messenger
    Rats
    Rats, Sprague-Dawley
    Receptors, Cannabinoid
    Receptors, Drug
    Reserpine
    Septum of Brain
    Sulfur Radioisotopes
    Transcription, Genetic

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    11358453

    Citation

    Silverdale, M A., et al. "Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-treated Rat Model of Parkinson's Disease." Experimental Neurology, vol. 169, no. 2, 2001, pp. 400-6.
    Silverdale MA, McGuire S, McInnes A, et al. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol. 2001;169(2):400-6.
    Silverdale, M. A., McGuire, S., McInnes, A., Crossman, A. R., & Brotchie, J. M. (2001). Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology, 169(2), pp. 400-6.
    Silverdale MA, et al. Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-treated Rat Model of Parkinson's Disease. Exp Neurol. 2001;169(2):400-6. PubMed PMID: 11358453.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. AU - Silverdale,M A, AU - McGuire,S, AU - McInnes,A, AU - Crossman,A R, AU - Brotchie,J M, PY - 2001/5/19/pubmed PY - 2001/7/6/medline PY - 2001/5/19/entrez SP - 400 EP - 6 JF - Experimental neurology JO - Exp. Neurol. VL - 169 IS - 2 N2 - High levels of both endocannabinoids and endocannabinoid receptors are present in the basal ganglia. Attention has recently focused on the role of endocannabinoids in the control of movement and in movement disorders of basal ganglia origin such as Parkinson's disease. We investigated CB1 cannabinoid receptor mRNA expression in the reserpine-treated rat model of Parkinson's disease using in situ hybridization. Reserpine treatment caused a topographically organized reduction in CB1 receptor mRNA expression in the striatum (ranging from 11.6% medially to 53.6% laterally and dorsally). No change in CB1 receptor mRNA expression was observed in the cerebral cortex or septum. This reduction in CB1 receptor mRNA expression may be secondary to increased endocannabinoid stimulation of the receptor as increased basal ganglia endocannabinoid levels have been shown to occur in this model of Parkinson's disease. The data support the idea that cannabinoid receptor antagonists may provide a useful treatment for the symptoms of Parkinson's disease. SN - 0014-4886 UR - https://www.unboundmedicine.com/medline/citation/11358453/Striatal_cannabinoid_CB1_receptor_mRNA_expression_is_decreased_in_the_reserpine_treated_rat_model_of_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-4886(01)97649-6 DB - PRIME DP - Unbound Medicine ER -